Bicycle Therapeutics Plc (BCYC)
7.07
-0.07
(-0.98%)
USD |
NASDAQ |
Dec 05, 16:00
7.075
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 490.43M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -63.20% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 17.28 |
| Price to Book Value | 1.102 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0105 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 89.91% |
Profile
| Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom. |
| URL | http://bicycletherapeutics.com |
| Investor Relations URL | https://investors.bicycletherapeutics.com/ |
| HQ State/Province | Cambridgeshire |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom. |
| URL | http://bicycletherapeutics.com |
| Investor Relations URL | https://investors.bicycletherapeutics.com/ |
| HQ State/Province | Cambridgeshire |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Feb. 24, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |